Targeting Tumor Endothelial Cells by EGCG Using Specific Liposome Delivery System Inhibits Vascular Inflammation and Thrombosis
Open Access
- 4 December 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (23) , e70462
Abstract
Background: Inflammation is one of the hallmarks of cancer and is associated with tumor growth. Tumor endothelial cells (TECs) demonstrate inflamed phenotypes. Endothelial inflammation initiates thrombus formation, which is the second cause of cancer‐related deaths. Epigallocatechin‐3‐O‐gallate (EGCG), a natural compound in green tea, has demonstrated an anti‐inflammatory effect. However, the tumor progression inhibition effect of EGCG by targeting TEC inflammation remains unclear. This study addresses the anti‐tumor effect of EGCG, especially its anti‐inflammatory role in TECs.Methods: In vitro, the effect of EGCG on TECs were studied using real‐time quantitative PCR and immunofluoresence to analyza gene and protein expression. In vivo, a cyclic RGD liposome delivery system (MEND) was employed to efficiently deliver EGCG to TECs in tumor‐bearing mice.Results: In vitro, EGCG significantly reduces inflammatory cytokine expression, including tumor necrosis factor‐α, interleukin‐6, IL‐8, and IL‐1β through NF‐κB signaling inhibition. Additionally, von Willebrand factor reduction in TECs, which is involved in platelet adhesion and thrombosis formation, was analyzed. Our results revealed that EGCG‐MEND significantly inhibited TEC inflammation and thrombus formation in tumors. Additionally, EGCG‐MEND improved tumor immunity by reducing programmed death‐ligand 1 expression and promoting high endothelial venule formation by recruiting CD8+ T cells.Conclusion: Our results indicate the anti‐tumor potential of EGCG‐MEND in normalizing the inflammatory immune microenvironment and inhibiting thrombosis by targeting TEC.Keywords
Funding Information
- BIKEN Foundation
- Japan Society for the Promotion of Science (JP21H03019, JP21H04840, JP21K10107, JP22K19610)
- Japan Agency for Medical Research and Development
This publication has 88 references indexed in Scilit:
- EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells.2004
- Redox Regulation of Reactive Oxygen Species-Induced p38 MAP Kinase Activation and Barrier Dysfunction in Lung Microvascular Endothelial CellsAntioxidants & Redox Signaling, 2003
- Leukocyte‐endothelial cell adhesion: avenues for therapeutic interventionBritish Journal of Pharmacology, 1999
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- Leukocyte-endothelial adhesion and angiogenesis in tumorsCancer and Metastasis Reviews, 1996
- Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cellsThe Journal of Immunology, 1996
- Production of large amounts of hydrogen peroxide by human tumor cells.1991
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986
- Growth factors and cancer.1986
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971